Australia Approves Anika’s Monovisc for Treatment of Osteoarthritis Pain

Anika Therapeutics was granted regulatory approval in Australia for Monovisc, its single injection viscosupplement for the treatment of pain associated with osteoarthritis of all synovial joints, including the hip and knee.

Monovisc is commercially available in more than twenty countries, including the United States, Canada, and various European countries.

The device recently received approval in India and Taiwan.